CD52 and neoplasm: The combination of YM155 with alemtuzumab, an anti-CD52 monoclonal antibody, in a murine model of human adult T-cell leukemia (ATL) significantly prolonged the survival of tumor-bearing mice, and all the mice that received the combination therapy survived and were tumor-free > 6 months after treatment [110].